FOR ADULTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA

LIVE PROGRESSION FREE

In 2 different trials, more people lived progression free when treated with sarclisa given with other therapies

How sarclisa may help

Living progression free means living without your multiple myeloma getting worse.
Trial 1:
At an average follow-up of 20.7 months, 74% (133 of 179 people) lived progression free with sarclisa + Kyprolis® (carfilzomib) and dexamethasone (Kd) vs 59% (73 of 123 people) treated with Kd alone. Trial 2: At an average follow-up of 11.6 months, 53% (81 of 154 people) lived progression free with SARCLISA + Pomalyst® (pomalidomide) and dexamethasone (Pd) vs 42% (64 of 153 people) treated with Pd alone.

sarclisa was proven
in two Phase 3 trials.

See the results

sarclisa is a targeted
immunotherapy that works
together with your
immune system.

See how it works
CareASSIST by Sanofi Genzyme

CareASSIST helps eligible patients with access and support for sarclisa.

Find out more
Watch SARCLISA Stories

SARCLISA Stories

Hear from people who are living with previously treated multiple myeloma or caring for someone who is.